Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
82.37
-0.06 (-0.07%)
At close: Oct 9, 2026, 4:00 PM EDT
81.23
-1.14 (-1.38%)
After-hours: Oct 9, 2026, 4:39 PM EDT
Dianthus Therapeutics Revenue
Dianthus Therapeutics had revenue of $761.00K in the quarter ending June 30, 2026, with 294.30% growth. This brings the company's revenue in the last twelve months to $1.90M, down -60.77% year-over-year. In the year 2025, Dianthus Therapeutics had annual revenue of $2.04M, down -67.35%. That makes Dianthus Therapeutics the 42,449th largest company in the world by revenue and 5,791st in the United States.
Revenue (ttm)
$1.90M
Revenue Growth
-60.77%
P/S Ratio
2,419.81
Revenue / Employee
$20,696
Employees
92
Market Cap
4.61B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | -4.20M | -67.35% |
| Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
| Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
| Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
| Dec 31, 2021 | 1.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.01B |
| Travere Therapeutics | 591.33M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| CRISPR Therapeutics AG | 13.39M |
| Relay Therapeutics | 10.35M |
DNTH News
- 8 days ago - Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting - GlobeNewsWire
- 21 days ago - Dianthus files automatic mixed securities shelf - TheFly
- 4 weeks ago - Dianthus initiated with an Overweight at JPMorgan - TheFly
- 4 weeks ago - Dianthus Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Dianthus Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 5 weeks ago - Dianthus initiated with a Buy at Citi - TheFly
- 5 weeks ago - Dianthus Therapeutics to Participate in Three Investor Conferences During September - GlobeNewsWire